Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating

Core Insights - Viking Therapeutics, Inc. (NASDAQ:VKTX) is identified as one of the best short squeeze stocks to consider for investment, with a Buy rating and a price target of $102 from H.C. Wainwright following the completion of enrollment in its VANQUISH-1 obesity trial [1][2] Group 1: Clinical Trials - The VANQUISH-1 trial enrolled approximately 4,650 individuals and concluded ahead of schedule, comparing three different doses to a placebo over a 78-week period [2] - The VANQUISH-2 trial is currently enrolling around 1,100 participants with type 2 diabetes who are also obese or overweight, expected to be completed in the first quarter of 2026 [2] Group 2: Research Findings - Viking Therapeutics released exploratory analysis data from its Phase 2 VENTURE trial, showing significant improvements in cardiometabolic measures among obese patients, with 78% of prediabetic individuals receiving VK2735 achieving normal glycemic control after 13 weeks, compared to 29% in the placebo group [3] Group 3: Company Overview - Viking Therapeutics is a clinical-stage biopharma company focused on developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases such as X-linked adrenoleukodystrophy (X-ALD) [4]